title: Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels.
abstract: To gain insight into determinants that define the duration of the asymptomatic period preceding AIDS, groups of long-term asymptomatic (LTA) person (> 7 years of follow-up) and slow and rapid progressors of human immunodeficiency virus infection were studied. LTAs had no clinical manifestations of AIDS or immunologic abnormalities in 7 years of follow-up. RNA copy numbers, gag- and env-specific, and neutralizing antibody titers in serum were determined 1 and 5 years after seroconversion or entry into the cohort. Early in infection, before immunologic markers or clinical manifestations allowed group discrimination, subjects who were later classified as LTAs had significantly less serum viral RNA than progressors. No significant increase in virus load was found in progressors, indicating that the initial load defines clinical outcome. In slow progressors, high virus load was associated with high p24-specific antibody titers, suggesting that delay of clinical manifestations of AIDS may be related to the presence of high levels of p24-specific but not V3-specific antibodies.
authors.affiliation: Human Retrovirus Laboratory, University of Amsterdam, Netherlands.
authors.forename: E
authors.initials: E
authors.lastname: Hogervorst
authors.forename: S
authors.initials: S
authors.lastname: Jurriaans
authors.forename: F
authors.initials: F
authors.lastname: de Wolf
authors.forename: A
authors.initials: A
authors.lastname: van Wijk
authors.forename: A
authors.initials: A
authors.lastname: Wiersma
authors.forename: M
authors.initials: M
authors.lastname: Valk
authors.forename: M
authors.initials: M
authors.lastname: Roos
authors.forename: B
authors.initials: B
authors.lastname: van Gemen
authors.forename: R
authors.initials: R
authors.lastname: Coutinho
authors.forename: F
authors.initials: F
authors.lastname: Miedema
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000821:virology; D000595:Amino Acid Sequence; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D018450:Disease Progression; D005500:Follow-Up Studies; D015483:HIV Antibodies / Q000097:blood*; D016655:HIV Core Protein p24 / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D015700:HIV Envelope Protein gp41 / Q000276:immunology; D015658:HIV Infections / Q000276:immunology / Q000821:virology*; D015497:HIV-1 / Q000254:growth & development* / Q000276:immunology; D018451:Homosexuality, Male; D006801:Humans; D008297:Male; D008969:Molecular Sequence Data; D009426:Netherlands; D009500:Neutralization Tests; D010446:Peptide Fragments / Q000276:immunology; D012367:RNA, Viral / Q000097:blood*; D016415:Sequence Alignment
chemical_list: D015483:HIV Antibodies; D016655:HIV Core Protein p24; D015699:HIV Envelope Protein gp120; D015700:HIV Envelope Protein gp41; C059762:HIV envelope protein gp120 (305-321); D010446:Peptide Fragments; D012367:RNA, Viral